NRX Pharmaceuticals (NRXP) vs Stablecoin Development (SDEV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Stablecoin Development (SDEV) over the past year, losing 21.0% versus a loss of 66.8%. Over five years, NRXP leads with a -97.2% price change compared with -99.9% for SDEV. NRX Pharmaceuticals is the larger company by market cap ($125.1 million vs $103.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRXP | SDEV |
|---|---|---|
| Share price | $2.89 | $1.99 |
| Market cap | $125.12M | $102.99M |
| 1-day change | -0.34% | -28.42% |
| YTD return | +7.01% | -92.94% |
| 1-year return | -20.98% | -66.83% |
| 5-year return | -97.17% | -99.94% |
| EPS (TTM) | $-0.58 | $-21.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.06 | $99.75 |
| 52-week low | $1.62 | $0.78 |
| Distance from 52-week high | -42.83% | -98.01% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +1232.18% | — |
| Average volume | 865.49K | 11.74M |
| Shares outstanding | 43.30M | 51.75M |
| Employees | 29 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed SDEV by 45.9 percentage points over the past year.
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Stablecoin Development
SDEV stock →Stablecoin Development Corporation engages in the accumulation and holding of digital assets for participation in blockchain-based networks. The company focuses on the accumulation, holding, and deployment of SKY, a protocol token of the decentralized Sky Protocol.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
NRXP vs SDEV FAQ
Which is bigger, NRX Pharmaceuticals or Stablecoin Development?
NRX Pharmaceuticals (NRXP) is larger, with a market capitalization of $125.12M compared with $102.99M for Stablecoin Development (SDEV).
Which stock has performed better over the past year, NRXP or SDEV?
NRXP returned -20.98% over the past 12 months, compared with -66.83% for SDEV (price return, excluding dividends). Past performance does not predict future results.
Are NRX Pharmaceuticals and Stablecoin Development in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.